![]() |
|
|
My Amedeo
FAQ
Privacy
About
|
For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF |
| Ovarian Neoplasms |
|
Free Subscription
1 Cancer |
Retrieve available abstracts of this week’s articles:
HTML format |
| Single Articles |
AMEDEO Ovarian Neoplasms is free of charge.
Progression-free survival and overall survival in the first-line treatment of
BRCA wild-type advanced epithelial ovarian cancer: An analysis of patient-level
data pooled from historical clinical trials.
Cancer. 2026;132:e70630.
PubMed
Abstract available
Inhibition of Translesion DNA Synthesis Sensitizes BRCA-Deficient Ovarian Cancer
to PARP Inhibitors.
Cancer Res. 2026 Sep 28. doi: 10.1158/0008-5472.CAN-26-1379.
PubMed
Abstract available
Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor
Resistance.
Cancer Res. 2026;86:4934-4954.
PubMed
Abstract available
Real-world clinical efficacy of pembrolizumab in combination with bevacizumab and
oral metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian
cancer.
Gynecol Oncol. 2026;214:22-26.
PubMed
Abstract available
BRCA1/2 Carriers With Breast-Ovarian Double Primary Cancers Versus Ovarian Cancer
Alone: Mutation Profiles and Survival Outcomes.
Int J Cancer. 2026 Oct 1. doi: 10.1002/ijc.70759.
PubMed
Abstract available
Nuclear cathepsin L induces DNA damage by regulating DNA repair factors in
ovarian cancer.
Oncogene. 2026 Oct 1. doi: 10.1038/s41388-026-04001.
PubMed
Abstract available
Thank you for your interest in scientific medicine.